A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Trial Profile

A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2016

At a glance

  • Drugs Dasotraline (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; Registrational
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 10 May 2016 Status changed from active, no longer recruiting to completed.
    • 08 Apr 2015 Planned number of patients changed from 600 to 700, as reported by ClinicalTrials.gov.
    • 08 Apr 2015 Planned End Date changed from 1 Oct 2016 to 1 Apr 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top